New nasal spray aims to soothe seasonal allergy misery
NCT ID NCT07219849
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new nasal spray called ALDP001 for people with seasonal allergic rhinitis (hay fever). Researchers want to find the best dose and how often to use it to reduce symptoms like sneezing, stuffy nose, and runny nose. About 164 adults will take part, and their symptoms will be tracked over 8 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ALDP001 nasal spray
- What this could lead to
- If successful, this could provide a new treatment option to ease nasal allergy symptoms like sneezing and congestion.
- What could go wrong
- This is an early Phase 2 trial with only 164 participants, so results may not apply to everyone. The treatment may not work better than a placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEASONAL ALLERGIC RHINITIS (SAR) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cliantha Research
RECRUITINGMississauga, Ontario, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.